Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9S3P7)

Drug Name

PF-06473871 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hypertrophic scars	EE60	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting CCN2 messenger RNA (CCN2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RXI-109	DMXG9ES	Fibrosis	GA14-GC01	Phase 2	[3]
OLX10010	DMXL7HO	Hypertrophic scars	EE60	Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT02205476) A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study. U.S. National Institutes of Health.
2	A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring. Plast Reconstr Surg Glob Open. 2018 Sep 6;6(9):e1861.
3	The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019 Jun;18(6):421-446.
4	Clinical pipeline report, company report or official report of Olix Pharmaceuticals.